


# Clinical research in cancer palliative care: a metaresearch analysis

Marie Vinches <sup>1,2</sup>, Anouk Neven,<sup>3</sup> Laurène Fenwarth,<sup>1</sup> Mitsumi Terada,<sup>4</sup> Giovanna Rossi,<sup>1</sup> Sarah Kelly,<sup>5,6</sup> Julien Peron,<sup>7</sup> Muriel Thomaso,<sup>8</sup> Mogens Grønvold,<sup>9</sup> Teresa De Rojas<sup>1</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjspcare-2019-002086>).

<sup>1</sup>Medical Department, EORTC Headquarters, Brussels, Belgium

<sup>2</sup>Medical Oncology Department, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France

<sup>3</sup>Statistics Department, EORTC Headquarters, Brussels, Belgium

<sup>4</sup>International Trials Management Section, Clinical Research Support Office, National Cancer Center Hospital, Chuo-ku, Japan

<sup>5</sup>Fellowship Program, SIOP Europe, Brussels, Belgium

<sup>6</sup>Data Management Department, EORTC Headquarters, Brussels, Belgium

<sup>7</sup>Medical Oncology Department, Cancer Institute of the "Hospices Civils" of Lyon, Lyon, France

<sup>8</sup>Supportive Care Department, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France

<sup>9</sup>Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark

## Correspondence to

Dr Marie Vinches, EORTC, Brussels 1200, Belgium; [vinchesmarie@gmail.com](mailto:vinchesmarie@gmail.com)

Received 23 October 2019

Revised 30 January 2020

Accepted 10 February 2020

Published Online First

24 March 2020



© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Vinches M, Neven A, Fenwarth L, et al. *BMJ Supportive & Palliative Care* 2020;**10**:249–258.

## ABSTRACT

**Objective** This metaresearch of the clinicaltrials.gov database aims to evaluate how clinical research on palliative care is conducted within the setting of advanced cancer.

**Methods** Clinicaltrials.gov was searched to identify registered studies recruiting patients with cancer, and investigating issues relevant to palliative care. The European Organisation for Research and Treatment of Cancer QLQ-C15-PAL (Quality of Life in palliative cancer care patients) questionnaire was taken into account to define the research domains of interest. Studies investigating cancer-directed therapy, management of cancer treatment-related adverse events and diagnostic tests were excluded. Publication status was crosschecked using PubMed.

**Results** Of 3950 identified studies, 514 were included. The most frequent reason for exclusion was cancer-directed therapy (2491). In 2007–2012, 161 studies were registered versus 245 in 2013–2018. Included studies were interventional (84%) or observational (16%). Most studies were monocentric (60%), sponsored by academia (79%), and conducted in North America (57%) or Europe (25%). Seventy-nine per cent of studies evaluated a heterogeneous population (>1 tumour type). Interventional studies most frequently investigated systemic drugs (34%), behavioural interventions (29%) and procedures for pain (24%). Pain, quality of life and physical function were the most frequently studied research domains (188, 95 and 52 studies, respectively). The most applied primary outcome measures were efficacy/symptom control (61%), quality of life (14%) and feasibility (12%). Only 16% of the closed studies had published results in PubMed.

**Conclusions** Our study describes the heterogeneous landscape of studies conducted to address the issues of patients with advanced cancer in palliative care. Albeit the observed increase in the number of studies over the last decade, the generalisation of the results brought by the existing trials is limited due to

methodological issues and lack of reporting.

A greater effort is needed to improve clinical research that supports evidence-based palliative cancer care.

## INTRODUCTION

Palliative care, as defined by WHO, 'is an approach that improves the quality of life (QoL) of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual'.<sup>1</sup> According to WHO, over 19 million patients worldwide are in need of palliative care every year, and 34% of them will die of cancer.<sup>2</sup>

Palliative care may be incorporated into patient management strategies at any stage of cancer, and integrated with tumour-directed treatment.<sup>3</sup> There is growing evidence of the benefit of providing palliative care as early as possible in patients with advanced cancer, as it has the potential to improve survival, as well as QoL.<sup>4,5</sup> In contrast, it has been shown that chemotherapy is deleterious when given during the last month of life. Many patients with cancer will reach a time where the best supportive care can be considered the best therapeutic option.<sup>6,7</sup> All patients who die of cancer are in need of palliative care.<sup>8</sup> Our study will focus within this setting on those patients which are no longer eligible to anticancer treatment.

Palliative care has evolved over time, and the oncology healthcare community has become increasingly aware of its importance.<sup>9,10</sup> Nevertheless, the literature in the field suggests that there is limited evidence-based care for patients with cancer in palliative and end-of-life settings.<sup>11,12</sup> The holistic aim of

palliative care makes it complex and challenging for clinical practice. It addresses multiple vital spheres of the patients and their families, including physical, emotional and social needs. Clinical research in this multifaceted setting brings several challenges. Historically, in the palliative care setting, slow recruitment and high attrition rates have made it difficult to carry out randomised controlled trials with sufficient sample size.<sup>13</sup> The ethical considerations in this patient population,<sup>14</sup> the lack of consensus and the multiplicity of available instruments to assess subjective outcomes (such as pain, fatigue or QoL), and the apparent insufficient research funding<sup>15</sup> pose some further difficulties for conducting studies in this setting.<sup>16</sup> Nevertheless, unmet needs remain and clinical research is still required to improve standards of care for patients with incurable cancer.<sup>17</sup>

This work analyses the current landscape of clinical research conducted in the palliative cancer setting, with the aim of better understanding the number and type of studies, study design and research topics. We present a meta-research study of the clinicaltrials.gov database with a quantitative and qualitative analysis of past and ongoing clinical trials and observational studies in patients with palliative cancer.

## MATERIAL AND METHODS

We performed a metaresearch analysis: a meta-research is a study of research itself and aims to understand and evaluate research practices.<sup>18 19</sup> The study methodology complies with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and guidelines, whenever applicable to the metaresearch context.<sup>20</sup>

### Study selection

Clinicaltrials.gov database<sup>21</sup> was searched to identify all studies registered before 1 January 2019, recruiting patients with cancer, and investigating issues relevant to palliative care. The decision on which issues to include was made by expert consensus, taking into account the European Organisation for Research and Treatment of Cancer QLQ-C15-PAL questionnaire.<sup>22</sup> The selected issues/search terms were: “anxiety”, “appetite”, “cognitive function”, “constipation”, “depression”, “dyspnoea”, “emotional function”, “fatigue”, “nausea”, “pain”, “palliative”, “quality of life”, “sleep disturbance” and “social function”. Two searches per issue/search term were performed in January 2019 according to the following search algorithm: [“metastatic cancer” or “advanced cancer”] + [issue search term].

Eligible studies were interventional or observational, including patients with any type of malignancy in an advanced setting (metastatic, late-stage disease, life-limiting); and investigating supportive care, that is, any supportive intervention meant to improve patients’ cancer-related symptoms, QoL, psychosocial

and/or spiritual issues. Radiotherapy or invasive procedures when delivered to primarily address pain and studies investigating palliative symptom biomarkers or diagnostic tools were included as well. Studies investigating the following interventions were excluded: disease-directed therapies (eg, chemotherapies, immunotherapies, surgery or advanced therapies such as cell therapies); drugs or procedures to treat cancer treatment-related adverse events; diagnostic or theranostic procedures (eg, imaging modalities, biomarkers).

The study screening on clinicaltrials.gov was performed by one investigator (MV). Eligibility of all identified studies was assessed by at least two investigators (TDR, LF, MT, SK, GR, MV). Data extraction was performed by one investigator and subsequently reviewed by the principal investigator (MV) for all studies. In case of discrepancy, the decision was taken by consensus of the investigators. Further data cleaning and validation were carried out by AN.

### Data extraction

Variables were partially extracted automatically from the clinicaltrials.gov database and were thereafter reviewed and manually encoded as needed through a standardised Microsoft Access 2016 file. Collected variables per study included baseline features (title, dates, location, sponsor), study design (type of study, design, randomisation, blinding, sample size), study population (age, life expectancy, disease), intervention(s), outcomes, palliative research domain, research field, use of patient-reported outcomes (PROs) and publication of results.

### Definition of variables


The studies were divided in two main groups, interventional and observational, according to the definition of study type by clinicaltrials.gov.

Location of the study was defined as the continent where the study took place: North America, Europe, Asia, Other (ie, Oceania, South America, Africa), or intercontinental when the study was international including sites from more than one continent.

The number of centres was categorised as monocentric, multicentric national and multicentric international.

Study status was categorised as follows: ongoing (including recruiting, enrolling by invitation, active not recruiting, and suspended), closed (including terminated and completed), not yet recruiting, withdrawn or unknown status. Actual sample size was only considered for closed trials and planned sample size as reported on clinicaltrials.gov was considered for all the other included trials.

When an industrial party was mentioned among the sponsors, the study was considered sponsored by industry. Otherwise, the sponsor was considered academic.



**Figure 1** Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.

Study design was defined as either single arm or multiarm for studies with two or more treatment groups or observational cohorts. We defined the study as blinded when any level of blinding (investigator, patient or reviewer) was reported.

The study population was categorised according to the selection criteria: any severe condition (ie, including patients with cancer and/or with other life-threatening conditions), any malignancy, any haematological malignancy, any solid tumour, multiple tumour types (ie, when inclusion was restricted to a limited number of malignancies), or single tumour type.

The variable ‘life expectancy’ was defined as the minimum or maximum estimated life expectancy to enter the study, as indicated within the selection criteria.

The interventions were classified in the following categories: systemic drug, topic drug, non-conventional therapies (acupuncture, herbal medicine, etc), palliative team consultation, behavioural/social/educational intervention (including physical activity), palliative diagnostic test/biomarker, procedure for pain or procedures for other symptoms. Procedure for pain included radiotherapy, high-intensity focused ultrasound (HIFU), MRI-guided HIFU (MR-HIFU), vertebral augmentation, radiofrequency, cryoablation, surgery, transcranial magnetic stimulation, photodynamic therapy, neurolysis and transectrical nerve stimulation.

The symptom or issue faced by the patient that was addressed by the study was defined as a ‘research domain’ and categorised as follows: fatigue, dyspnoea, pain, sleep disturbance, appetite, nausea, constipation, emotional function (including anxiety, depression), global QoL, social function, cognitive function, physical

function, healthcare planning and palliative care team performance.

The research domains were grouped into four research fields: biology (fatigue, dyspnoea, pain, sleep disturbance, appetite, nausea, constipation and physical function), psychology (emotional function, cognitive function, global QoL), sociology (social function) and ethics (healthcare planning, palliative care team performance).

Primary outcomes defined by the investigators and listed on clinicaltrials.gov were categorised as follows: efficacy (eg, symptom management, technique effectiveness), feasibility (including acceptability), global QoL, survival, quality of care (including care planning), epidemiology and biomarker evaluation. In studies with more than one primary outcome, all were collected.

When at least one of the primary outcome assessments was based on a PRO measure, the study was considered as ‘using PROs’. The availability of published results according to clinicaltrials.gov was crosschecked with PubMed.<sup>23</sup>

Evolution over time of the number of studies was restricted to the period after 2007 to avoid bias, as the clinicaltrials.gov registration requirements were expanded after the FDA Amendments Act of 2007 (FDAAA) passed.<sup>24</sup> The two 5-year periods, 2007–2012 and 2013–2018, were compared.

### Statistical analysis

Median and IQR were used to describe quantitative data. Percentages were used to describe qualitative data. Percentages may not always total 100% due to rounding error.

The SAS software V.9.4 (SAS) was used to perform the analysis and to plot the results.

## RESULTS

The clinicaltrials.gov database search resulted in 3950 studies; 514 (13%) were included (figure 1). The most frequent reason for exclusion was cancer-directed therapy (2491), followed by studies not including patients with cancer (567). Included studies were predominantly interventional (84%, 430/514) compared with observational studies (16%, 84/514). Between 2007 and 2012, 161 studies were registered versus 245 over the period 2013–2018 (online supplementary figure 1).

### Study characteristics

The main characteristics of the 514 included studies are shown in tables 1 and 2. Regarding the status of the studies, 32% (162) were ongoing, 54% (276) were closed and 15% (76) were either withdrawn, not yet recruiting or with unknown status. The study status was similar between interventional and observational studies. Among the 276 closed studies, 18% (51) had results available on clinicaltrials.gov and 16% (45) had results published in PubMed. Out of the 45 studies

**Table 1** Main study characteristics: operational, dissemination and design information

	Interventional	Observational	Overall
Number of studies	430	84	514
Operational			
Status			
Ongoing	134 (31%)	28 (33%)	162 (32%)
Closed	227 (53%)	49 (58%)	276 (54%)
Not yet recruiting	21 (5%)	2 (2%)	23 (5%)
Withdrawn	11 (3%)	1 (1%)	12 (2%)
Unknown status	37 (9%)	4 (5%)	41 (8%)
Sponsor			
Academic	339 (79%)	69 (82%)	408 (79%)
Industry	91 (21%)	15 (18%)	106 (21%)
Location			
North America	248 (58%)	44 (53%)	292 (57%)
Europe	97 (23%)	29 (35%)	126 (25%)
Asia	46 (11%)	6 (7%)	52 (10%)
Intercontinental	20 (5%)	4 (5%)	24 (5%)
Other	14 (3%)	1 (1%)	15 (3%)
Unknown	5 (1%)	–	5 (1%)
Number of centres			
Monocentric	257 (60%)	49 (58%)	306 (60%)
Multicentric national	119 (28%)	21 (25%)	140 (27%)
Multicentric international	24 (6%)	9 (11%)	33 (6%)
Unknown	30 (7%)	5 (6%)	35 (7%)
Dissemination			
Published results among closed studies* (n=276)			
Has results on clinicaltrials.gov	49 (22%)	2 (4%)	51 (18%)
Publication on PubMed	40 (18%)	5 (10%)	45 (16%)
Design			
Blinded			
No	286 (67%)	–	286 (56%)
Yes	144 (33%)	–	144 (28%)
Not applicable	–	84 (100%)	84 (16%)
Study arms			
Single arm	136 (32%)	67 (80%)	203 (39%)
Multiarmed	294 (68%)	17 (20%)	311 (61%)
Randomisation			
No	152 (35%)	–	152 (30%)
Yes	278 (65%)	–	278 (54%)
Not applicable	–	84 (100%)	84 (16%)
Number of primary outcomes			
1	337 (78%)	65 (77%)	402 (78%)
2	38 (9%)	5 (6%)	43 (8%)
≥3	42 (10%)	8 (10%)	50 (10%)
Unknown	13 (3%)	6 (7%)	19 (4%)
Actual sample size among closed studies (n=276)			
Median	60	74	60
IQR	21–150	38–255	23–177

Continued

**Table 1** Continued

	Interventional	Observational	Overall
Number of studies	221	49	270
Planned sample size among non-closed studies (n=238)			
Median	72	230	80
IQR	30–176	50–500	38–200
Number of studies	202	35	237

\*On clinicaltrials.gov, all trials with results were closed trials; nevertheless, we found additional publications on PubMed for 15 interventional not closed studies (seven ongoing trials, one not yet recruiting, two withdrawn and five unknown status)

with results published in PubMed, 15 were opened before 2007 and 24 were opened between 2007 and 2012. Most studies were sponsored by academia (79%, 408), and conducted in North America (57%, 292) or Europe (25%, 126). Sixty per cent (306) of the studies were monocentric and only 6% (33) were international multicentric studies. Among the interventional studies, 33% (144/430) were performed with blinding, and 65% (278/430) were randomised. Regarding closed studies (n=276), the median actual sample size was 60 patients (IQR 21–150) for interventional studies and 74 (IQR 38–255) for observational studies. The median duration of the studies was 3 years (IQR 2–4 years). Regarding the non-closed studies (n=238), the median planned sample size was 80 (IQR 38–200) overall. There were no apparent differences between the main characteristics of the observational and interventional studies, with the exception of the number of arms, where there was a majority of single arm designs (80%, 67/84) among the observational studies but a majority of multiarm trials (68%, 294/430) among the interventional studies. Complete data for the primary endpoint (palliative research domain) and most variables were available for all studies; unknown data were found for the variables ‘status’, ‘number of centres’, ‘location’ and ‘number of primary outcomes’, in less than 8% of the studies.

### Population

The studied population is shown in figure 2. Seventy-nine per cent of studies evaluated a heterogeneous population, including more than one tumour type: patients with any malignancy were included in 250 studies (49%); 80 studies (16%) included patients with any solid tumour; 60 studies (12%) included patients with multiple tumour types, and 14 studies (3%) included patients with any severe condition (ie, including non-malignant diseases) and one study (0.2%) was restricted to patients with only haematological malignancies. A hundred and nine studies (21%) were tumour specific. Of these 109 studies, 39% (42) included only breast, 26% (28) lung cancer, 15% (16) prostate and 3% (3) colorectal. The study

**Table 2** Main study characteristics: study population, study aim

	Interventional	Observational	Overall
Study population			
Condition			
Any severe condition	9 (2%)	5 (6%)	14 (3%)
Any malignancy	206 (48%)	44 (52%)	250 (49%)
Any haematological malignancy	1 (0%)	–	1 (0%)
Any solid tumour	71 (17%)	9 (11%)	80 (16%)
Multiple tumour types (restricted)	50 (12%)	10 (12%)	60 (12%)
Single tumour type	93 (22%)	16 (19%)	109 (21%)
Restricted to patients with bone metastases	145 (34%)	21 (25%)	166 (32%)
Age			
Minimum age			
≤17 years	31 (7%)	11 (13%)	42 (8%)
18 years	348 (81%)	65 (77%)	413 (80%)
19–64 years	48 (11%)	7 (8%)	55 (11%)
≥65 years	3 (1%)	1 (1%)	4 (1%)
Maximum age			
≤17 years	5 (1%)	–	5 (1%)
18–64 years	7 (2%)	2 (2%)	9 (2%)
65–120 years	65 (15%)	9 (11%)	74 (14%)
No upper limit	353 (82%)	73 (87%)	426 (83%)
Life expectancy			
Minimum life expectancy			
>1 week to <1 month	7 (2%)	4 (5%)	11 (2%)
≥1 to <3 months	33 (8%)	4 (5%)	37 (7%)
≥3 to <6 months	65 (15%)	9 (11%)	74 (14%)
≥6 months to <1 year	31 (7%)	2 (2%)	33 (6%)
≥1 year	9 (2%)	1 (1%)	10 (2%)
Not specified	285 (66%)	64 (76%)	349 (68%)
Maximum life expectancy			
≤6 months	5 (1%)	3 (4%)	8 (2%)
>6 months to ≤1 year	10 (2%)	4 (5%)	14 (3%)
≤2 years	2 (0%)	–	2 (0%)
Not specified	413 (96%)	77 (92%)	490 (95%)
Study aim			
Intervention			
Systemic drug	148 (34%)	–	148 (29%)
Behavioural intervention	125 (29%)	–	125 (24%)
Physical activity	20	–	20
Procedure for pain	103 (24%)	–	103 (20%)
Radiotherapy	48	–	48
MR-HIFU	16	–	16
Vertebral augmentation	12	–	12
Radiofrequency	8	–	8
Cryoablation	7	–	7
Surgery	4	–	4
Other	8	–	8

Continued

**Table 2** Continued

	Interventional	Observational	Overall
Palliative team consultation	24 (6%)	–	24 (5%)
Nonconventional therapies	16 (4%)	–	16 (3%)
Procedure for other symptom	9 (2%)	–	9 (2%)
Palliative diagnostic/biomarker	4 (1%)	–	4 (1%)
Topic drug	1 (0%)	–	1 (0%)
Not applicable	–	84 (100%)	84 (16%)
Research domain studied			
Pain	170 (40%)	18 (21%)	188 (37%)
Quality of life (global)	77 (18%)	18 (21%)	95 (19%)
Physical function	45 (10%)	7 (8%)	52 (10%)
Emotional function	31 (7%)	4 (5%)	35 (7%)
Healthcare planning	11 (3%)	15 (18%)	26 (5%)
Appetite/nutrition	20 (5%)	2 (2%)	22 (4%)
Social function	17 (4%)	5 (6%)	22 (4%)
Fatigue	17 (4%)	3 (4%)	20 (4%)
Palliative team performance	14 (3%)	5 (6%)	19 (4%)
Dyspnoea	17 (4%)	1 (1%)	18 (4%)
Cognitive function	5 (1%)	–	5 (1%)
Sleep disturbance	2 (0%)	3 (4%)	5 (1%)
Nausea	3 (1%)	1 (1%)	4 (1%)
Constipation	1 (0%)	2 (2%)	3 (1%)
Research field			
Biology	275 (64%)	37 (44%)	312 (61%)
Psychology	113 (26%)	22 (26%)	135 (26%)
Sociology	17 (4%)	5 (6%)	22 (4%)
Ethics	25 (6%)	20 (24%)	45 (9%)
Primary outcome*			
Efficacy/symptom control	277 (64%)	39 (47%)	316 (61%)
Quality of life	60 (14%)	13 (16%)	73 (14%)
Feasibility/acceptability	55 (13%)	5 (6%)	60 (12%)
Quality of care	25 (6%)	15 (18%)	40 (8%)
Safety	31 (7%)	2 (2%)	33 (6%)
Biomarker	10 (2%)	6 (7%)	16 (3%)
Survival	5 (1%)	1 (1%)	6 (1%)
Epidemiology	–	4 (5%)	4 (1%)
Evaluation of outcome with PROs			
Yes	262 (61%)	35 (42%)	297 (58%)
No	155 (36%)	43 (51%)	198 (39%)
NA	13 (3%)	6 (7%)	19 (4%)

\*Studies could have more than one primary outcome (see table 1 'Number of outcomes') therefore percentages do not sum up to 100%.

MR-HIFU, MRI-guided high-intensity focused ultrasound; NA, not applicable; PRO, patient-reported outcome.

population was restricted to patients with bone metastasis in 32% (166) of the studies.

The lower age limit for inclusion was 18 years of age for 80% (413) of the studies. The majority of studies



**Figure 2** Study population. (A) Eligible conditions for all studies. (B) Eligible cancer type for studies that only investigated one type of tumour.

did not define an upper age limit (83%, 426). Only five (1%) studies focused on the paediatric population (age <18 years), and four (1%) on the elderly population (age ≥65 years).

Life expectancy estimation was a defined selection criterion for 35% (180) of the studies. The majority of these studies (92%, 165/180) required a minimum life expectancy ranging from 1 week to 1 year. A maximum life expectancy was required in only 13% (24/180) of the studies, with the threshold being above 6 months in 16 studies.

### Intervention

Interventional studies most frequently investigated systemic drugs (34%, 148/430) or behavioural interventions (29%, 125/430). Systemic drugs investigated included bisphosphonates, antiemetics, pain medication and others. Physical activity was investigated in 16% (20/125) of the behavioural intervention studies. Other

behavioural interventions included educational interventions, communication and coping programme. Procedures for pain were investigated in 24% of the trials (103/430), using radiotherapy in 47% of them (48/103), MR-HIFU in 16% (16), vertebral augmentation in 12% (12) or other procedures for pain in 26% (27).

Other interventions included palliative team consultation (6%, 24/430), non-conventional therapies (4%, 16/430), procedures targeting other symptoms besides pain (2%, 9/430) and palliative biomarkers (1%, 4/430).

### Research domain and research field


Pain was the palliative research domain (ie, issue faced by the patient) investigated in the largest proportion of studies (37%, 188/514), followed by QoL and physical function (19% 95/514 and 10% 52/514 studies, respectively; figure 3). Fatigue, appetite and dyspnoea each represented only 4% of the studies. Observational studies investigated pain less often (21% vs 40%), and healthcare planning more often (18% vs 3%) than interventional trials.

The most studied research field was biology (61% of studies, 312/514), followed by psychology (26%, 135/514). Observational studies investigated ethics more often (24% vs 6%), and biology less often (44% vs 64%) than interventional trials.


### Outcome

One single primary outcome (ie, criteria defined by the investigator) was specified for 402 (78%) studies, 43 (8%) studies had 2 primary outcomes and 50 (10%) studies had 3 or more defined primary outcomes.

The most frequently applied primary outcomes were efficacy of the intervention or symptom control (61%, 316/514), QoL (14%, 73) and feasibility (12%, 60). Other primary outcomes were quality of care or care



**Figure 3** Number of trials per palliative research domain.



**Figure 4** Primary outcome used per palliative research domain, reported in percentages. Only studies with one primary outcome and studies with several primary outcomes belonging to the same category are displayed (n=454; 88%). QoL, quality of life.

planning (8%, 40), safety (6%, 33), biomarker (3%, 16), survival (1%, 6) and epidemiology (1%, 4). There were differences in the primary outcome between interventional and observational studies: efficacy/symptom control was applied in 64% versus 47%, quality of care in 6% versus 18% and feasibility in 13% versus 6%, respectively.

For the majority of research domains (11/14), efficacy/symptom control was the most investigated outcome (figure 4). For three research domains, other outcomes were more frequently used: for the studies investigating global QoL issues, QoL outcomes were predominantly applied; for healthcare planning and palliative care team performance domains, the most used outcome was quality of care/care planning.

PROs were used for the assessment of primary outcomes in 61% of the interventional trials and in 42% of the observational studies.

## DISCUSSION

Our study describes the heterogeneous landscape of studies conducted to address the issues of patients with advanced cancer in palliative care. The observed quantity and quality of the studies suggest that greater efforts are needed to improve clinical research that supports evidence-based palliative cancer care.

When searching for [Cancer] on [clinicaltrials.gov](http://clinicaltrials.gov), over 69 000 studies can be found (69 600 studies on 12 August 2019). Out of those, only 514 studies (0.8%) were identified in our metaresearch work as studies aiming to investigate palliative care for patients with advanced cancer. A proportionally small number of palliative care studies is conducted when compared with the total number of cancer research studies. We observed an increase in the number of studies over the last years (from 161 studies in 2007–2012 to 245 studies in 2013–2018), which constitutes a positive

sign of paradigm shift. Yet, even if palliative care awareness has progressed in the last decades, a great effort is still needed to improve the life of patients with advanced cancer.<sup>25</sup>

Over 9.5 million patients died of cancer worldwide in 2018.<sup>26</sup> However, in an ever-growing cancer research landscape, it is appalling to observe the low proportion of research dedicated to this patient population. Beyond the apparent quantitative deficit of cancer palliative research as observed in [clinicaltrials.gov](http://clinicaltrials.gov), our study shows qualitative shortfalls. In the era of personalised medicine, the ‘one size fits all’ approach is becoming obsolete. Personalised medicine can be considered in alignment with the scope of palliative care, as it falls within the scope of WHO concept of Universal Health Coverage (UHC): ‘UHC means that all individuals and communities receive the health services they need without suffering financial hardship. It includes the full spectrum of essential, quality health services, from health promotion to prevention, treatment, rehabilitation, and palliative care’.<sup>27</sup> Nevertheless, in the field of palliative care, patient management algorithms often do not rely on individualised medicine, but are rather symptom driven and cross tumoural. Consequently, trials investigating palliative care frequently include a very heterogeneous patient sample (49% of studies included patients with any malignancy). This approach may leave specific needs of particular patient populations unmet. Indeed, the physiopathology of symptoms may differ between different clinical settings, which should be taken into account to deliver the best treatment to patients. In addition to these biological factors, and again in alignment with WHO definition of UHC, broader determinants of health (including social, economic, environmental, as well as people’s characteristics and behaviours) should be considered and incorporated into future palliative care research.<sup>27 28</sup>

Another qualitative concern arises from the majority of studies identified in [clinicaltrials.gov](http://clinicaltrials.gov) being monocentric (60%) and with a limited sample size (median of 60 patients), which can have an impact on the power to detect differences between treatment strategies and on the generalisability of results. However, the methodology of the trials appears to be reliable, with a large proportion of the investigational trials using randomisation (65%) and blinding (34%) to minimise bias. These findings are to put in line with the fact that when considering palliative oncology literature, the majority of published studies consist of case report studies, with a lower level of evidence.<sup>29 30</sup>

Another relevant finding of our study is the unbalance across the studied research domains. Patients with incurable cancer bear a high symptom burden as they approach death<sup>31</sup>: fatigue, pain, lack of energy, weakness and appetite loss are the most frequent symptoms, occurring in more than half of patients.<sup>32</sup> According to Seow *et al*, pain, nausea, anxiety and

depression scores remain relatively stable over the last 6 months of life.<sup>31</sup> Nonetheless, shortness of breath, drowsiness, lack of appetite and tiredness increase in severity over time, particularly in the month before death. According to our study, pain is the research domain most often investigated (37%), but only 4% of the studies focus on the management of fatigue, and a further 4% on the management of appetite loss and nutritional problems—despite fatigue, pain and appetite loss being the most frequent symptoms in this patient population. Another alarming finding is that dyspnoea, one of symptoms that worsens at the end of life and is particularly devastating for the patient and caregivers, was only investigated in a small number of studies according to *clinicaltrials.gov* (n=18, 4%).<sup>31 33</sup> We acknowledge that the number of clinical trials may not accurately represent how extensively a research topic is studied. Furthermore, the relative scarcity of research in a certain domain could be illustrating the actual challenge in conducting studies in that area. This is particularly true in palliative care research, and it adds to the challenge of including severely ill patients in clinical trials, and to the existing high attrition rates.<sup>34</sup> Our study suggests that unmet needs remain, regarding the identification and the management of the burdensome symptoms associated with cancer progression and the last months of life. Further research is needed to answer the questions on how best to treat these symptoms. Additionally, the most studied research field was biology. While most oncology research studies are biology centred, a more holistic approach might be particularly desirable for palliative care research, expanding the research interests to the fields of psychology, sociology and ethics.<sup>35 36</sup>

As defined by WHO, palliative care aims to improve the QoL of the patients facing life-threatening illness by means of a multidisciplinary approach.<sup>1</sup> Our study identified efficacy/symptom control as the most used primary outcome (61%), while QoL per se was less frequently used as a primary endpoint (14%). However, symptom control is correlated to health-related QoL and may be considered as a surrogate measure of QoL in the palliative setting.<sup>37</sup> Furthermore, more than 50% of the studies identified in *clinicaltrials.gov* used PROs to measure the primary outcome. These encouraging findings align with the current multistakeholder push to promote patient-centred research.<sup>38 39</sup> In fact, the field of QoL has been exponentially expanding since the 1980s.<sup>40</sup> QoL is not to be understood as a single health index, but as the essence of palliative care, considering the patient's well-being as a whole.<sup>41 42</sup>

It is worrisome that despite the limited number of palliative care research studies in *clinicaltrials.gov*, the results seem to be insufficiently shared with the scientific community. Among the closed studies included in our work, only 16% had results available on PubMed and 18% on *clinicaltrials.gov*. While this is not a problem unique to the palliative care setting with an

estimated general publication rate of 46% in medical research, the proportion of published results in palliative care research seems particularly low.<sup>43 44</sup>

The limitations of our work need to be acknowledged. The study search was limited to *clinicaltrials.gov* only, and restricted within certain research domains. This database is being more and more used to evaluate research practices; however, understanding the limitations of the database is crucial to perform a valid analysis.<sup>45</sup> While *clinicaltrials.gov* is the largest publicly available database, we may have underestimated the number of studies as some may not be registered, especially observational studies, which can be of particular relevance in the palliative care field. Furthermore, we have to acknowledge the dynamic nature of *clinicaltrials.gov*, as the incentives for reporting trials have changed over time. Including two key policy changes for clinical trial reporting on *clinicaltrials.gov*: the 2005 requirement by the International Committee of Medical Journal Editors to register all clinical trials as a condition for publication of results<sup>46</sup> and the 2007 requirement by the FDAAA to register non-phase 1 clinical trials of drug and biological products, as well as non-feasibility trials of device products.<sup>24</sup> An other limiting aspect includes the possible under-representation of trials conducted out of Western countries and the lack of data regarding the ability of specific groups of patients to participate in trials.<sup>47</sup> In spite of these shortfalls, *clinicaltrials.gov* remains the largest publicly available trial database, and we believe it to be better suited for the proposed research question, as it takes most registered trials into account. Moreover, a search based on published results (eg, a PubMed search) would only have yielded 60 studies (11.7%, 60/514) of those that we were able to identify at *clinicaltrials.gov*, and hence would have substantially limited the scope of our research question.

While the investment in palliative care has increased over time, a limited number of studies have been conducted to address the issues of patients with advanced cancer who are not receiving active oncological treatment. Furthermore, the generalisation of the results brought by the existing trials is limited due to methodological issues and lack of reporting. Therefore, a greater effort is needed to improve clinical research that supports evidence-based palliative care for patients with incurable cancer.

**Twitter** Marie Vinches @VinchesMarie and Sarah Kelly @1Sarah\_M\_Kelly

**Contributors** All authors have taken part in the planning and reporting of the work described in the article. TDR, LF, MT, SK, GR and MV conducted the data extraction. MV and AN conducted the data review and validation. All authors contributed to the manuscript, have reviewed and agreed upon the manuscript content. MV is responsible for the overall content as guarantor.



**Funding** Marie Vinches, Laurene Fenwarth and Julien Peron's work as Fellows was supported by a grant from Fonds Cancer (FOCA), Teresa de Rojas, Mitsumi Terada and Giovanna Rossi's by a grant from the EORTC Cancer Research Fund (ECRF) and Sarah Kelly's by a grant from the European Society for Paediatric Oncology (SIOPE).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository. <https://clinicaltrials.gov/>; ClinicalTrials.gov data are available to all requesters, both within and outside the United States, at no charge.

#### ORCID iD

Marie Vinches <http://orcid.org/0000-0001-5147-2321>

## REFERENCES

- WHO. Who definition of palliative care., 2012. Available: <https://www.who.int/cancer/palliative/definition/en/> [Accessed 12 Aug 2019].
- World Palliative Care Alliance. Global atlas of palliative care at the end of life, 2014. Available: <http://www.who.int/cancer/publications/palliative-care-atlas/en/>
- Kaasa S, Loge JH, Aapro M, *et al.* Integration of oncology and palliative care: a Lancet oncology Commission. *Lancet Oncol* 2018;19:e588–653.
- Ferrell BR, Temel JS, Temin S, *et al.* Integration of palliative care into standard oncology care: American Society of clinical oncology clinical practice guideline update. *J Clin Oncol* 2017;35:96–112.
- Temel JS, Greer JA, Muzikansky A, *et al.* Early palliative care for patients with metastatic Non–Small-Cell lung cancer. *N Engl J Med* 2010;363:733–42.
- Greer JA, Pirl WF, Jackson VA, *et al.* Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. *J Clin Oncol* 2012;30:394–400.
- Näppä U, Lindqvist O, Rasmussen BH, *et al.* Palliative chemotherapy during the last month of life. *Ann Oncol* 2011;22:2375–80.
- Murtagh FEM, Bausewein C, Verne J, *et al.* How many people need palliative care? A study developing and comparing methods for population-based estimates. *Palliat Med* 2014;28:49–58.
- Schrijvers D, Cherny NI. ESMO clinical practice guidelines on palliative care: advanced care planning. *Ann Oncol* 2014;25 Suppl 3:iii138–42.
- García-Baquero Merino MT. Palliative care: taking the long view. *Front Pharmacol* 2018;9:1140.
- Bouça-Machado R, Rosário M, Alarcão J, *et al.* Clinical trials in palliative care: a systematic review of their methodological characteristics and of the quality of their reporting. *BMC Palliat Care* 2017;16:10.
- Kaasa S, Hjermstad MJ, Loge JH. Methodological and structural challenges in palliative care research: how have we fared in the last decades? *Palliat Med* 2006;20:727–34.
- Khalil H, Ristevski E. The challenges of evidence-based palliative care research. *Int J Evid Based Healthc* 2018;16:136–7.
- Abernethy AP, Capell WH, Aziz NM, *et al.* Ethical conduct of palliative care research: enhancing communication between Investigators and institutional review boards. *J Pain Symptom Manage* 2014;48:1211–21.
- Higginson IJ. Research challenges in palliative and end of life care. *BMJ Support Palliat Care* 2016;6:2–4.
- Aoun SM, Nekolaichuk C. Improving the evidence base in palliative care to inform practice and policy: thinking outside the box. *J Pain Symptom Manage* 2014;48:1222–35.
- Ferris FD, Bruera E, Cherny N, *et al.* Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of clinical oncology. *J Clin Oncol* 2009;27:3052–8.
- Ioannidis JPA, Fanelli D, Dunne DD, *et al.* Meta-research: evaluation and improvement of research methods and practices. *PLoS Biol* 2015;13:e1002264.
- Ioannidis JPA. Meta-research: why research on research matters. *PLoS Biol* 2018;16:e2005468.
- Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009;6:e1000100.
- Home. Clinicaltrials.Gov. Available: <https://clinicaltrials.gov/ct2/home> [Accessed 12 Aug 2019].
- Groenvold M, Petersen MA, Aaronson NK, *et al.* The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. *Eur J Cancer* 2006;42:55–64.
- Home - PubMed - NCBI. Available: <https://www.ncbi.nlm.nih.gov/pubmed/>
- FDA. Food and drug administration amendments act (FDAAA) of 2007. Available: <https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-administration-amendments-act-fdaaa-2007> [Accessed 12 Aug 2019].
- Visser C, Hadley G, Wee B. Reality of evidence-based practice in palliative care. *Cancer Biol Med* 2015;12:193–200.
- Bray F, Ferlay J, Soerjomataram I, *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–424.
- Universal health coverage (UHC). Available: [https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-\(uhc\)](https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc))
- Wagstaff A, Neelsen S. A comprehensive assessment of universal health coverage in 111 countries: a retrospective observational study. *Lancet Glob Health* 2020;8:e39–49.
- Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009) - CEBM. Available: <https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
- Hui D, Parsons HA, Damani S, *et al.* Quantity, design, and scope of the palliative oncology literature. *Oncologist* 2011;16:694–703.
- Seow H, Barbera L, Sutradhar R, *et al.* Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. *J Clin Oncol* 2011;29:1151–8.
- Teunissen SCCM, Wesker W, Kruitwagen C, *et al.* Symptom prevalence in patients with incurable cancer: a systematic review. *J Pain Symptom Manage* 2007;34:94–104.
- Thomas JR, von Gunten CF. Clinical management of dyspnoea. *Lancet Oncol* 2002;3:223–8.
- Hui D, Glitza I, Chisholm G, *et al.* Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. *Cancer* 2013;119:1098–105.
- Carrieri D, Peccatori FA, Boniolo G. Supporting supportive care in cancer: the ethical importance of promoting a holistic conception of quality of life. *Crit Rev Oncol Hematol* 2018;131:90–5.
- Van Beek K, Siouta N, Preston N, *et al.* To what degree is palliative care integrated in guidelines and pathways for adult cancer patients in Europe: a systematic literature review. *BMC Palliat Care* 2016;15:26.

- 37 Mooney K, Berry DL, Whisenant M, *et al.* Improving cancer care through the patient experience: how to use patient-reported outcomes in clinical practice. *Am Soc Clin Oncol Educ Book* 2017;37:695–704.
- 38 Europe I. *Manifesto for a new approach for better medicine in Europe establishing treatment optimization as part of personalized medicine development.* , 2019: 376, 710–3.
- 39 Kempf E, Bogaerts J, Lacombe D, *et al.* 'Mind the gap' between the development of therapeutic innovations and the clinical practice in oncology: a proposal of the European organisation for research and treatment of cancer (EORTC) to optimise cancer clinical research. *Eur J Cancer* 2017;86:143–9.
- 40 Sirgy MJ, Michalos AC, Ferriss AL, *et al.* The Quality-of-Life (QOL) research movement: past, present, and future. *Soc Indic Res* 2006;76:343–466.
- 41 The world Health organization quality of life assessment (WHOQOL): position paper from the world Health organization. *Soc Sci Med* 1995;41:1403–9.
- 42 Staquet M, Berzon R, Osoba D, *et al.* Guidelines for reporting results of quality of life assessments in clinical trials. *Qual Life Res* 1996;5:496–502.
- 43 Ross JS, Mulvey GK, Hines EM, *et al.* Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. *PLoS Med* 2009;6:e1000144.
- 44 Hudson KL, Collins FS. Sharing and reporting the results of clinical trials. *JAMA* 2015;313:355–6.
- 45 Tse T, Fain KM, Zarin DA. How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider. *BMJ* 2018;361:k1452.
- 46 De Angelis C, Drazen JM, Frizelle FA, *et al.* Clinical trial registration: a statement from the International Committee of medical Journal editors. *N Engl J Med* 2004;351:1250–1.
- 47 Durham TA. How did these data get here? recommendations for the analysis of data from ClinicalTrials.gov. *Ther Innov Regul Sci* 2019;53:639–40.